Received Jul 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Sick; This non-serious case was reported by a consumer via call center representative and described the occurrence of sickness in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of pyrexia (1st dose received in 2024, for tolerance refer linked case US2025079195). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced sickness (Verbatim: Sick). The outcome of the sickness was unknown. It was unknown if the reporter considered the sickness to be related to Shingrix. It was unknown if the company considered the sickness to be related to Shingrix. Linked case(s) involving the same patient: US2025079195 Additional Information: GSK Receipt Date: 24-JUN-2025 This case was reported by the parent of the patient. The reporter mentioned that her daughter (patient) had a reaction to Shingrix. When questioned about the event, she was reluctant to provide any information, only saying that her daughter received both doses of Shingrix a few months ago in 2024 and the 2nd shot made her a little sicker in 2024. She did not wish to provide any further information on behalf of her daughter without her daughter's consent.; Sender's Comments: US-GSK-US2025079195:Same patinet dose 1st/ same reporter